Price to Sales (P/S)
since 2005
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Biogen Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 1, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 2, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Biogen Inc. Annual Report.
The analyzed financial data reveal distinct trends in share price, sales per share, and price-to-sales (P/S) ratio over the period from early 2006 to early 2022.
- Share Price
- The share price exhibited a generally upward trajectory from 2006 until reaching a peak around 2015, with notable fluctuations. Starting at $45.50 in 2006, it increased steadily, experiencing significant gains between 2011 and 2015, peaking at $391.12 in early 2015. After reaching this apex, the share price showed a downward trend with some volatility, dropping to $220.17 by early 2022. This decline after 2015 indicates a correction phase or response to market or company-specific challenges.
- Sales per Share
- Sales per share demonstrated consistent growth throughout the period, indicative of expanding revenue relative to the number of shares outstanding. Beginning at $7.04 in 2006, this metric climbed steadily year-over-year, peaking at $88.26 in early 2021. However, there was a slight decrease to $74.72 by early 2022, suggesting a recent moderation in sales growth or potential operational challenges.
- Price-to-Sales (P/S) Ratio
- The P/S ratio showed significant variability. From 2006 to 2010, the ratio declined from 6.46 to 3.33, possibly reflecting a faster increase in sales relative to share price growth or a valuation adjustment. Between 2010 and 2015, the P/S ratio rose sharply, reaching a peak of 10.26 in early 2014, corresponding with the surge in share price. Thereafter, the ratio declined to approximately 2.95 by 2022, indicating that the share price decreased faster than sales per share in the latter years of the dataset. This reduction suggests a more conservative valuation by the market or a correction following earlier exuberance.
Overall, the data illustrate a period of growth in sales per share accompanied initially by increasing share prices and valuation multiples, culminating in 2014-2015. Subsequent years show a retracement in share prices and valuation ratios despite continued sales growth until 2021, with some recent softness in sales per share noted in 2022. These patterns may reflect changes in market sentiment, competitive dynamics, or company performance factors influencing investor perceptions and valuation.
Comparison to Competitors
Biogen Inc., P/S, long-term trends, comparison to competitors
| Biogen Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | |||||||||||||
| Feb 3, 2021 | |||||||||||||
| Feb 6, 2020 | |||||||||||||
| Feb 6, 2019 | |||||||||||||
| Feb 1, 2018 | |||||||||||||
| Feb 2, 2017 | |||||||||||||
| Feb 3, 2016 | |||||||||||||
| Feb 4, 2015 | |||||||||||||
| Feb 6, 2014 | |||||||||||||
| Feb 5, 2013 | |||||||||||||
| Feb 3, 2012 | |||||||||||||
| Feb 4, 2011 | |||||||||||||
| Feb 9, 2010 | |||||||||||||
| Feb 6, 2009 | |||||||||||||
| Feb 14, 2008 | |||||||||||||
| Feb 21, 2007 | |||||||||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Biogen Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Biogen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 3, 2022 | ||
| Feb 3, 2021 | ||
| Feb 6, 2020 | ||
| Feb 6, 2019 | ||
| Feb 1, 2018 | ||
| Feb 2, 2017 | ||
| Feb 3, 2016 | ||
| Feb 4, 2015 | ||
| Feb 6, 2014 | ||
| Feb 5, 2013 | ||
| Feb 3, 2012 | ||
| Feb 4, 2011 | ||
| Feb 9, 2010 | ||
| Feb 6, 2009 | ||
| Feb 14, 2008 | ||
| Feb 21, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Biogen Inc., P/S, long-term trends, comparison to industry (health care)
| Biogen Inc. | Health Care | |
|---|---|---|
| Feb 3, 2022 | ||
| Feb 3, 2021 | ||
| Feb 6, 2020 | ||
| Feb 6, 2019 | ||
| Feb 1, 2018 | ||
| Feb 2, 2017 | ||
| Feb 3, 2016 | ||
| Feb 4, 2015 | ||
| Feb 6, 2014 | ||
| Feb 5, 2013 | ||
| Feb 3, 2012 | ||
| Feb 4, 2011 | ||
| Feb 9, 2010 | ||
| Feb 6, 2009 | ||
| Feb 14, 2008 | ||
| Feb 21, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).